The Medicines Company to Present at UBS Global Life Sciences Conference
Posted on: Friday, 23 September 2005, 18:00 CDT
The Medicines Company (NASDAQ: MDCO) is scheduled to present at the UBS Global Life Sciences Conference on Thursday, September 29th at noon Eastern time.
Clive Meanwell, Chairman and Chief Executive Officer, is expected to discuss company operations, Angiomax(R) (bivalirudin) marketing and development updates for Angiomax, clevidipine and cangrelor.
The session will be webcast with a link available at The Medicines Company's website: http://www.themedicinescompany.com.
About The Medicines Company
The Medicines Company meets the demands of the world's most advanced medical practitioners by developing products that improve acute hospital care. The Company markets Angiomax(R) (bivalirudin), an anti-clotting therapy approved in the U.S. and other countries for use in patients undergoing coronary angioplasty, a procedure to clear restricted blood flow in arteries around the heart. The Medicines Company creates value using its range of clinical and commercial skills to develop products acquired from leading life science innovators.
Source: Business Wire
Related Articles
- Medicines Company Receives Not Approvable Letter From FDA for Angiomax
- Medicines Company's Angiomax Shows Improved Outcomes in Heart Attack Patients
- Medicines Company Submits Angiomax Application to FDA
- The Medicines Company Submits Angiomax(R) (Bivalirudin) sNDA to Expand Label to Include ACUITY Data
- The Medicines Company Products Angiomax(R) (Bivalirudin) and Cleviprex(TM) (Clevidipine) Featured in Three Late Breaking Trials at American College of Cardiology Annual Scientific Session
- Study Suggests Angiomax Safer for Heart Patients
- The New England Journal of Medicine Publishes Angiomax(R) (Bivalirudin) ACUITY Trial Results
- The Medicines Company Completes Enrollment of 13,800-Patient ACUITY Trial of Angiomax(R) (Bivalirudin)
- FDA Approves Expansion of the Medicines Company's Angiomax-R- -Bivalirudin- Label; Prescribing Information Now Includes Data From REPLACE-2 Trial
- The Medicines Company's Angiomax-R- -Bivalirudin- Saves Hospital Costs, Says Publication in Journal of the American College Of Cardiology
 |
 |
User Comments (0)
RSS Feeds